DCE-MRI联合DWI评估乳腺癌新辅助化疗疗效方面的研究进展
Research Progress of DCE-MRI Combined with DWI in Evaluating the Efficacy of Neo-adjuvant Chemotherapy for Breast Cancer
DOI: 10.12677/ACM.2024.141202, PDF,   
作者: 程 瑜, 姚 娟*：新疆医科大学第一附属医院影像中心，新疆 乌鲁木齐
关键词: DCE-MRI；DWI；乳腺癌；新辅助化疗；DCE-MRI； DWI； Breast Cancer； Neoadjuvant Chemotherapy
摘要: 据世界卫生组织最新发布的研究表明，乳腺癌的发生率已经超过肺癌，成为全球第一大恶性肿瘤，我国乳腺癌的病例数量上升至每年约42万人，并且近年来发病率每年递增3%~4%，但乳腺癌并非是一种不治之症，新辅助化疗(Neoadjuvant Chemotherapy, NAC)是一种全身化疗，包括在手术消融前对病变进行局部放疗，它在一定程度上降低了癌细胞转移的风险，并尽可能缩小病灶，这有助于后续的手术干预来控制患者的病情，从而防止其持续进展。因此越早检测出乳腺肿瘤，延长患者生存周期的几率越大。既往研究表明，NAC后达到病理完全缓解(pCR)的患者比非Pcr (部分缓解或无缓解)的患者显著延长了总生存期(OS)和无病生存期(DFS)。随着技术的逐步发展，弥散加权成像DWI (diffusion weighted imaging, DWI)和动态对比增强(Dynamic Contrast-Enhanced Magnetic Reso-nance Imaging, DCE-MRI)等功能性磁共振成像(magnetic resonance imaging, MRI)技术，也广泛用于乳腺疾病的诊断中。本篇综述主要探讨DCE-MRI联合DWI评价新辅助化疗在评估乳腺癌新辅助化疗疗效方面的研究进展。
Abstract: According to the latest research released by the World Health Organization, the incidence of breast cancer has exceeded lung cancer, becoming the world’s largest malignant tumor, about 420,000 new patients with breast cancer in China every year, and in recent years, the incidence of annual increase of 3%~4%, but breast cancer is not an incurable disease. Neoadjuvant Chemotherapy (NAC) refers to systemic chemotherapy with local radiotherapy to the lesion before surgical resec-tion, which to some extent reduces the risk of cancer cell metastasis, shrinks the lesion as much as possible, and facilitates subsequent surgical intervention to control the patient’s disease, thus pre-venting the disease from continuing to progress . Therefore, the earlier a breast tumor is detected, the greater the chance of prolonging a patient’s survival cycle. Previous studies have shown that pa-tients who achieve pathologically complete response (pCR) after NAC have significantly longer over-all survival (OS) and disease-free survival (DFS) than patients who do not have a pCR (partial re-sponse or no response). With the gradual development of the technology, diffusion weighted imag-ing (DWI) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), Functional magnetic resonance imaging (MRI) techniques, such as DCE-MRI, are also widely used in the diag-nosis of breast diseases. This review focuses on the research progress of DCE-MRI combined with DWI in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer.
文章引用：程瑜, 姚娟. DCE-MRI联合DWI评估乳腺癌新辅助化疗疗效方面的研究进展[J]. 临床医学进展, 2024, 14(1): 1406-1411. https://doi.org/10.12677/ACM.2024.141202

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clini-cians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[3] Conforti, F., Pala, L., Sala, I., Oriecuia, C., De Pas, T., Specchia, C., et al. (2021) Evaluation of Pathological Complete Response as Surrogate Endpoint in Neoadjuvant Randomised Clinical Trials of Early-Stage Breast Cancer: Systematic Review and Meta-Analysis. BMJ, 375, e066381. [Google Scholar] [CrossRef] [PubMed]
[4] Li, J. and Jiang, Z. (2022) Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2022: Stratification and Classification. Cancer Biology & Medicine, 19, 769-773. [Google Scholar] [CrossRef] [PubMed]
[5] Dubsky, P., Pinker, K., Cardoso, F., Montagna, G., Rit-ter, M., Denkert, C., et al. (2021) Breast Conservation and Axillary Management after Primary Systemic Therapy in Pa-tients with Early-Stage Breast Cancer: The Lucerne Toolbox. The Lancet Oncology, 22, e18-e28. [Google Scholar] [CrossRef] 
[6] Lee, S.C., Grant, E., Sheth, P., et al. (2017) Accuracy of Contrast-Enhanced Ultrasound Compared with Magnetic Resonance Imaging in Assessing the Tumor Response after Neoadjuvant Chemotherapy for Breast Cancer. Journal of Ultrasound in Medicine, 36, 901-911. [Google Scholar] [CrossRef] [PubMed]
[7] Man, V.C. and Cheung, P.S. (2017) Neoadjuvant Chemotherapy In-creases Rates of Breast-Conserving Surgery in Early Operable Breast Cancer. Hong Kong Medical Journal, 23, 251-257. [Google Scholar] [CrossRef] [PubMed]
[8] Boughey, J.C., Mccall, L.M., Ballman, K.V., et al. (2014) Tumor Biol-ogy Correlates with Rates of Breast-Conserving Surgery and Pathologic Complete Response after Neoadjuvant Chemo-therapy for Breast Cancer: Findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Annals of Surgery, 260, 608-616. [Google Scholar] [CrossRef] 
[9] Ahmed, S.H. (2019) Safety of Neoadjuvant Chemotherapy for the Treatment of Breast Cancer. Expert Opinion on Drug Safety, 18, 817-827. [Google Scholar] [CrossRef] [PubMed]
[10] Comes, M.C., La Forgia, D., Didonna, V., Fanizzi, A., Giotta, F., Latorre, A., et al. (2021) Early Prediction of Breast Cancer Recurrence for Patients Treated with Neoadjuvant Chemotherapy: A Transfer Learning Approach on DCE- MRIs. Cancers, 13, Article No. 2298. [Google Scholar] [CrossRef] [PubMed]
[11] Tahmassebi, A., Wengert, G.J., Helbich, T.H., Bago-Horvath, Z., Alaei, S., Bartsch, R., et al. (2019) Impact of Machine Learning with Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Pa-tients. Investigative Radiology, 54, 110-117. [Google Scholar] [CrossRef] 
[12] Suo, S., Yin, Y., Geng, X., Zhang, D., Hua, J., Cheng, F., et al. (2021) Diffusion-Weighted MRI for Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: Evaluation with Mono-, Bi-, and Stretched-Exponential Models. Journal of Translational Medicine, 19, Article No. 236. [Google Scholar] [CrossRef] [PubMed]
[13] Chen, H., Li, W., Wan, C. and Zhang, J. (2022) Correlation of Dynamic Contrast-Enhanced MRI and Diffusion-Weighted MR Imaging with Prognostic Factors and Subtypes of Breast Cancers. Frontiers in Oncology, 12, Article ID: 942943. [Google Scholar] [CrossRef] [PubMed]
[14] Shangguan, A.J., Sun, C., Wang, B., Pan, L., Ma, Q., Hu, S., Yang, J., et al. (2019) DWI and DCE-MRI Approaches for Differentiating Reversibly Electroporated Penumbra from Ir-reversibly Electroporated Ablation Zones in a Rabbit Liver Model. American Journal of Cancer Research, 9, 1982-1994.
[15] Ling, D.C., Sutera, P.A., Iarrobino, N.A., Diego, E.J., Soran, A., Johnson, R.R., et al. (2019) Is Mul-tifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era after Neoadjuvant Chemo-therapy and Breast Conservation Therapy? International Journal of Radiation Oncology, Biology, Physics, 104, 869-876. [Google Scholar] [CrossRef] [PubMed]
[16] Yoshikawa, K., Ishida, M., Kan, N., Yanai, H., Tsuta, K., Sekimoto, M., et al. (2020) Direct Comparison of Magnetic Resonance Imaging and Pathological Shrinkage Patterns of Triple-Negative Breast Cancer after Neoadjuvant Chemotherapy. World Journal of Surgical Oncology, 18, Article No. 177. [Google Scholar] [CrossRef] [PubMed]
[17] Zheng, C.H., Liu, Z.Y., Yuan, C.X., Dong, X.Y., Li, H.M., Wang, J.J., et al. (2021) Mutant Allele Frequency-Based Intra-Tumoral Genetic Heterogeneity Related to the Tumor Shrinkage Mode after Neoadjuvant Chemotherapy in Breast Cancer Patients. Frontiers in Medicine (Lausanne), 8, Arti-cle ID: 651904. [Google Scholar] [CrossRef] [PubMed]
[18] Fukada, I., Araki, K., Kobayashi, K., Shibayama, T., Takahashi, S., Gomi, N., et al. (2018) Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer. Radiology, 286, 49-57. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, S., Zhang, Y., Yang, X., Fan, L., Qi, X., Chen, Q., et al. (2013) Shrink Pattern of Breast Cancer after Neoadjuvant Chemotherapy and Its Correlation with Clinical Pathological Factors. World Journal of Surgical Oncology, 11, Article No. 166. [Google Scholar] [CrossRef] [PubMed]
[20] Kong, X., Moran, M.S., Zhang, N., Haffty, B. and Yang, Q. (2011) Meta-Analysis Confirms Achieving Pathological Complete Response after Neoadjuvant Chemotherapy Predicts Favourable Prognosis for Breast Cancer Patients. European Journal of Cancer, 47, 2084-2090. [Google Scholar] [CrossRef] [PubMed]
[21] Luangdilok, S., Samarnthai, N. and Korphaisarn, K. (2014) Associ-ation between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Ad-vanced Breast Cancer Patients. Journal of Breast Cancer, 17, 376-385. [Google Scholar] [CrossRef] [PubMed]
[22] Braman, N.M., Etesami, M., Prasanna, P., Dubchuk, C., Gilmore, H., Tiwari, P., Plecha, D. and Madabhushi, A. (2017) Intratumoral and Peritumoral Radiomics for the Pretreatment Pre-diction of Pathological Complete Response to Neoadjuvant Chemotherapy Based on Breast DCE-MRI. Breast Cancer Research, 19, Article No. 57. [Google Scholar] [CrossRef] [PubMed]
[23] Partridge, S.C., Zhang, Z., Newitt, D.C., Gibbs, J.E., Chenevert, T.L., Rosen, M.A., et al. (2018) Diffusion-Weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treat-ment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology, 289, 618-627. [Google Scholar] [CrossRef] [PubMed]
[24] Symmans, W.F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) Measurement of Residual Breast Cancer Burden to Predict Survival after Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 25, 4414-4422. [Google Scholar] [CrossRef] 
[25] Suo, S., Yin, Y., Geng, X., Zhang, D., Hua, J., Cheng, F., Chen, J., Zhuang, Z., Cao, M. and Xu, J. (2021) Diffusion-Weighted MRI for Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: Evaluation with Mono-, Bi-, and Stretched-Exponential Models. Journal of Transla-tional Medicine, 19, Article No. 236. [Google Scholar] [CrossRef] [PubMed]
[26] Gu, Y.L., Pan, S.M., Ren, J., Yang, Z.X. and Jiang, G.Q. (2017) Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Meta-Analysis. Clinical Breast Cancer, 17, 245-255. [Google Scholar] [CrossRef] [PubMed]
[27] Li, X.R., Cheng, L.Q., Liu, M., Zhang, Y.J., Wang, J.D., Zhang, A.L., et al. (2012) DW-MRI ADC Values Can Predict Treatment Response in Patients with Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy. Medical Oncology, 29, 425-431. [Google Scholar] [CrossRef] [PubMed]

为你推荐